[AeroLyn]Aerolyn Launches Dual Commercial Processes for Amenamevir, Empowering Global Clients in Japan & International Markets
2026西湖龙井茶官网DTC发售：茶农直供，政府溯源防伪到农户家
Aerolyn has officially launched two commercial manufacturing processes for Amenamevir, precisely tailored to meet the regulatory, patent, and quality requirements of both the Japanese market and global overseas markets. The company provides one-stop compliant and efficient raw material solutions for generic pharmaceutical enterprises.
For the Japanese market, Aerolyn adopts a patent-avoiding manufacturing process that ensures no infringement on relevant Japanese patents, effectively reducing clients’ registration risks. This supports accelerated generic drug development and assists clients in being listed in the PMDA production approval directory, speeding up market entry.
For global overseas markets, leveraging advanced crystallization and micronization technologies, Aerolyn achieves stable crystal forms, precise particle size control, and exceptional quality. The product meets international high standards in purity, impurity control, and batch-to-batch consistency, and has gained recognition and stable partnerships from clients across multiple countries.
Backed by a robust quality system and large-scale supply capacity, Aerolyn’s Amenamevir delivers core advantages of dual processes, superior quality, and accelerated registration. It empowers partners to efficiently develop anti-viral formulations against herpes zoster and achieve shared success in the global pharmaceutical market.
Aerolyn 凌岚生物针对阿莫奈韦（Amenamevir） 推出双商业化生产工艺已正式落地，精准适配日本市场与全球海外市场的法规、专利及质量要求，为仿制药企业提供一站式合规、高效的原料解决方案。
面向日本市场，凌岚生物采用专利规避工艺，可确保产品不侵犯日本相关专利，有效降低客户申报风险，支持快速开展仿制药开发，并可协助客户加速上市进程。
面向海外全球市场，公司凭借优势成本的同时采用先进的结晶与微粉化技术，实现晶型稳定、粒径精准可控、质量水平优异，在纯度、杂质控制与批次一致性上达到国际高标准，已获得多个国家客户的认可与稳定合作。
依托成熟的质量体系与规模化供应能力，凌岚生物阿莫奈韦以双工艺、高质量、快注册的核心优势，助力合作伙伴高效开发带状疱疹等抗病毒制剂，共赢全球医药市场。
请先 登录后发表评论 ~